Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Thyroid Cancer Clinical Trials

Review the thyroid cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 34

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Status: Active
Location: 12 locations
A Study of Avutometinib and Defactinib in Patients with Thyroid Cancer
Status: Active
Location: 8 locations
Larotrectinib with Radioactive Iodine for the Treatment of Patients with Metastatic Differentiated Thyroid Cancer with NTRK Fusions, LANTERN Trial
Status: Active
Location: 4 locations
Dabrafenib, Trametinib, and IMRT in Treating Patients with BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Active
Location: 4 locations
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
Status: Active
Location: 4 locations
SLV-154 Treatment of Metastatic Solid Tumors
Status: Active
Location: 4 locations
Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Treatment of Pembrolizumab in Metastatic or Unresectable Anaplastic/Undifferentiated Thyroid Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Selpercatinib Prior to Radioiodine Therapy for the Treatment of Children, Adolescents, and Young Adults with Metastatic Differentiated Thyroid Cancers that Harbor a RET Fusion, RAISE Trial
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Radiation Therapy and Radioactive Iodine for the Treatment of Recurrent Papillary or Follicular Thyroid Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
XL092 and Cemiplimab for the Treatment of BRAF V600E-Wild Type Anaplastic Thyroid Cancer, NEO-COMBAT XL Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Active
Location: See ClinicalTrials.gov
Lower Dose Versus Standard Dose Lenvatinib for the Treatment of Symptomatic or Progressive Radioactive Iodine Resistant Differentiated Thyroid Cancer
Status: Approved
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Patient Decision Aid in Supporting Decision-Making about When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients with Medullary Thyroid Cancer and Their Caregivers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
New PET Scan (68Ga-FAPI-46) for People with Cancers
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
New MRI Biomarkers in Head and Neck Cancers
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
An Educational Intervention (CQUPLE) for Decreasing Over-treatment of Patients with Low-risk Thyroid Cancer
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Status: Active
Location: 5 locations